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Background: Cardiovascular complications are the leading cause of mortality and morbidity in Marfan syndrome
(MFS), a dominantly inherited disorder caused by mutations in the gene that encodes fibrillin-1. There are approximately
18,000 patients in the UK with MFS. Current treatment includes careful follow-up, beta blockers, and prophylactic
surgical intervention; however, there is no known treatment which effectively prevents the rate of aortic dilatation in
MFS. Preclinical, neonatal, and pediatric studies have indicated that angiotensin receptor blockers (ARBs) may reduce
the rate of aortic dilatation. This trial will investigate the effects of irbesartan on aortic dilatation in Marfan syndrome.
Methods/Design: The Aortic Irbesartan Marfan Study (AIMS) is an investigator-led, prospective, randomized,
placebo-controlled, double-blind, phase III, multicenter trial. Currently, 26 centers in the UK will recruit 490 clinically
confirmed MFS patients (aged ≥6 to ≤40 years) using the revised Ghent diagnostic criteria. Patients will be randomized
to irbesartan or placebo. Aortic root dilatation will be measured by transthoracic echocardiography at baseline and
annually thereafter. The primary outcome is the absolute change in aortic root diameter per year measured by
echocardiography. The follow-up period will be a minimum of 36 months with an expected mean follow-up period
of 48 months.
Discussion: This is the first clinical trial to evaluate the ARB irbesartan versus placebo in reducing the rate of aortic root
dilatation in MFS. Not only will this provide useful information on the safety and efficacy of ARBs in MFS, it will also
provide a rationale basis for potentially lifesaving therapy for MFS patients.
Trial registration: ISRCTN, 90011794Background
Cardiovascular complications are the leading cause of
mortality and morbidity in Marfan syndrome (MFS), a
dominantly inherited disorder caused by mutations in
the gene that encodes fibrillin-1. There are approxi-
mately 18,000 patients in the UK with MFS. MFS is
diagnosed clinically using the Ghent criteria which em-
phasizes the identification of a positive family history,
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reproduction in any medium, provided the orsystemic score of clinical features [1,2]. Twenty-five per-
cent of cases are the result of a new mutation in the
fibrillin-1 gene, and are often more seriously affected
than familial cases [3]. Gene mutations in FBN1 have
been demonstrated in 92% of classically affected MFS
type 1 cases [4,5]. Other genes capable of causing famil-
ial ascending thoracic aortic aneurysms are now being
described, but these families can usually be differentiated
clinically from MFS [6-9].
Aneurysmal dilatation of the aortic root is the most
serious cardiovascular manifestation of MFS. This results
from weakening of the tissues within the aortic wall and
consequent reduced ability to contain the forces associatedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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eurysms is expansion over many years followed by dissec-
tion and rupture and premature death. In addition,
myxomatous valve changes with insufficiency of the mitral
and aortic valves, and progressive myocardial dysfunction
can also occur and require intervention, and a wide range
of non-cardiac manifestations affecting skeletal and ocular
systems result in significant morbidity and mortality. The
average age at death of an untreated MFS patient is
32 years [10].
Current treatment includes careful follow-up and pro-
phylactic surgical intervention to replace the aneurysmal
root when the risk of spontaneous dissection or rupture
exceeds that of surgery. For most patients this risk is
judged by the size of the aortic root, with the standard
threshold at which patients are usually considered for
prophylactic surgical treatment being 50 mm [11]. In
some patients with an adverse family history, or where
pregnancy is considered or where rapid dilatation is ob-
served, surgical intervention may be considered at diam-
eters below 50 mm.Medical treatment
The goal of medical therapy in MFS is to slow or arrest
the development of clinical manifestations of MFS. With
respect to the cardiovascular system, the current gold
standard for medical treatment is with oral beta
blockers. Beta blocker therapy has been shown in retro-
spective and prospective studies to reduce the rate of
aortic root dilatation [12-15], and is associated with an
increase in life span [16]. The mechanism is unknown
but is likely to be mediated through reduction in left
ventricular ejection force, blood pressure, and pulse
pressure, all of which potentially reduce aortic wall
stress. However, recent studies in children with MFS
and a meta-analysis have cast doubt on the efficacy of
beta blocker therapy [17]. Furthermore, many patients
cannot tolerate beta blockers (approximately 25% to 50%
of MFS patients), either because they have asthma,
which affects about 20% of MFS children, or because of
intolerable side effects including dizziness, nightmares,
and lethargy, or can only tolerate them in small doses.
Furthermore, beta blocker therapy does not alter the
underlying process that results in weakness and dilata-
tion of the aortic wall.Fibrillin-1
Fibrillin-1 is the major component of extracellular myo-
fibrils which form the backbone of the elastic tissues in
the extracellular matrix. Original hypotheses of the
pathogenesis of MFS were based on a simple model of
aortic dilatation occurring as a mechanical consequence
of abnormal elastic tissues. However, such a hypothesisdoes not explain many manifestations of MFS including
excessive growth and abnormal alveolar septation.
Elucidating the mechanisms of aortic dilatation has
been facilitated by the development of an MFS knockout
mouse. The so-called mgR mouse has an identical muta-
tion of fibrillin-1 as that seen in human MFS and the
mutant allele produces structurally normal fibrillin-1
protein at 15% of the normal level. The mouse manifests
all the clinical features of human MFS including the
mouse equivalent of postnatally-acquired aortic disease
and death by aortic dissection, as well as lung and skel-
etal findings [18,19]. Homozygous mgR mice die be-
tween 3 and 6 months of age of dissecting aortic
aneurysm. The mice show loss of structural integrity of
the aortic wall with cystic medial necrosis, histologically
identical to that seen in human MFS. Breach of the elas-
tic laminae in fibrillin-1 mutant mice is believed to allow
infiltration of inflammatory cells into the media, result-
ing in intense elastolysis associated with increased ex-
pression of matrix metalloproteinases (MMPs) [20].
Research in this mouse model has elucidated a much
more complex role for fibrillin-1 in the regulation of
extracellular activity of transforming growth factor beta
(TGF-β). Abnormal fibrillin-1 leads to excess activity of
TGF-β in extracellular tissues and this appears to con-
tribute to the pathogenesis of many of the phenotypic
features of MFS [21]. Myxomatous changes of the mitral
valve in mutant mice were correlated with excess TGF-β
signaling, and prevented by TGF-β antagonism in vivo
[22]. Furthermore, increased TGF-β signaling in associ-
ation with increased MMP expression was also observed
in the dura and aortic wall of fibrillin-1-deficient mice
[23]. These mice were shown to have excess immunore-
active free TGF-β, and systemic administration of a
TGF-β neutralizing antibody rescued lung morphogen-
esis in fibrillin-1-deficient mice, and attenuated changes
in the aortic wall.
The renin-angiotensin system and TGF-β regulation
Extracellular TGF-β is also regulated by the autocrine
molecule angiotensin II. Activation of the angiotensin II
receptor type 1 (AT1) can increase the production of
TGF-β, which may be responsible for many of the cellu-
lar events in the tissue of patients with MFS including
proliferation of vascular smooth muscle cells and levels
of MMPs. By contrast, activation of the angiotensin II
receptor type 2 (AT2) has beneficial effects on aortic
wall homeostasis. Selective inhibition of the AT1 recep-
tor therefore offers a therapeutic target to favorably
modify the pathogenesis of tissue injury in MFS. AT1 re-
ceptor blockers (ARBs) include a number of commonly
used antihypertensive medications including losartan
and irbesartan. In the experimental mouse, ARB admin-
istration resulted in a clinically relevant decrease in
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reduced tissue expression of TGF-β-responsive genes, and
reduced levels of intracellular mediators within the TGF-β
signaling cascade, such as phosphorylated Smad2.
Habashi et al. [24] reported that five young Marfan
mice were given 0.6 g/L of losartan, consumed through
their drinking water for a period of 6 to 10 months. An-
other group of ten MFS mice were given a placebo, and
a third group of seven MFS mice were given a dose of
0.5 g/L of propranolol, a beta blocker. A fourth group of
eleven wild-type mice without MFS served as a control
group. The mice studied were 2 months old when ther-
apy was started, equivalent to human teenage years.
These mice already had enlarged aortas. After the mice
were treated for 6 months, examination of the aorta his-
tologically showed losartan, as opposed to placebo or
propranolol, prevented elastic fiber fragmentation, and
blunted TGF-β signaling in the aortic media. Addition-
ally, echocardiographic measurements of aortic root
growth in losartan MFS mice were comparable to the
normal control group of mice (P = 0.55), and the abso-
lute aortic root diameter between losartan MFS mice
and the normal control group at the end of treatment
was also similar (P = 0.32). Losartan MFS mice also
showed significant improvement in aortic wall thickness
and aortic wall architecture compared to placebo, and
normalization relative to the normal control group. In
comparison, propranolol-treated MFS mice showed a
slower rate of aortic growth compared to the placebo
group (P <0.001), but showed no effect on aortic wall
thickness or aortic wall architecture compared to the
placebo group, thus limiting its effect in slowing the rate
of aortic growth.
Therefore it is particularly attractive to consider the
use of an ARB, which both lowers blood pressure compar-
ably with beta blocker therapy [25-28] (a known positive
effect in MFS) and leads to a clinically relevant decrease
of TGF-β signaling [29,30]. These data support the hy-
pothesis that many features of MFS are probably due to
failure of proper regulation of TGF-β function [31,32].
ARBs in human MFS
Pilot data of 18 severe neonatal MFS cases [33,34]
treated with losartan [31] indicated that placing an af-
fected infant on an ARB was associated with a reduction
in the rate of aortic root dilatation. Preliminary data in-
dicated the average change in aortic root diameter pre-
losartan treatment was 3.5 mm/yr and following losartan
treatment was 0.5 mm/yr. This compares with an aver-
age change in aortic root diameter of 1.67 mm/yr in pa-
tients treated with beta blockers alone. This pilot data
suggests that a clinical trial of an ARB may demonstrate
effects more specific than, and probably additive to, beta
blockers [35-37].In the Aortic Irbesartan Marfan Study (AIMS), we
wish to translate the pre-clinical, neonatal, and pediatric
work into a randomized clinical trial (RCT) to investi-
gate whether the ARB irbesartan can reduce aortic dila-
tation in patients with MFS compared to placebo. All
patients will receive standard treatments including beta
blocker therapy if tolerated. We believe this will provide
additional information regarding the effects of combined
therapy as well as the effects in patients intolerant of
beta blockers. Furthermore, we propose to examine the
effects of irbesartan in a wider age range, extending the
upper adult age limit to 40 years, since patients are often
first diagnosed in adulthood.
A study funded by the National Institute of Health
(NIH) of losartan versus beta blocker is being carried
out in the USA. This study has recruited 604 patients
and is also evaluating effects on aortic dilatation [38].
The USA study has a different design to the one de-
scribed in this protocol, since the AIMS trial is compar-
ing irbesartan versus placebo, but the two trials will
provide complementary information on this important
question.
It is widely accepted that aortic root dilatation is the
hallmark of serious cardiovascular complications in
MFS. Furthermore, aortic root dilatation is usually the
major factor considered in referring patients for surgery.
Therefore, while being a surrogate outcome measure,
clinical outcome and the decision to intervene are dir-
ectly related to aortic dilatation. We have considered
conducting a clinical outcome study in MFS (evaluating
the effects of irbesartan on rates of death, aortic surgery,
or other serious cardiovascular complications) but this
study would probably take 10 years or more to complete
in order to assess the true long-term effects of treat-
ment. For this reason we have selected the rate of aortic
root dilatation as the primary outcome measure. We be-
lieve that the main benefit of ARB treatment will be in
the prevention of aortic complications when applied as a
prophylactic measure in patients with MFS who are ei-
ther in their growing years or in adulthood prior to the
development of severe dilatation. We consider that this
is too long to wait to introduce a potentially lifesaving
treatment for young patients at risk of severe complica-
tions. It is important to be aware of the level of evidence
needed to introduce a new treatment for MFS, but the
carefully considered opinion of the MFS experts collab-
orating in this study is that a significant reduction in
aortic dilatation would provide important clinical bene-
fits to patients, and that this measure is a robust surro-
gate for clinical outcomes. Previous studies that showed
the benefits of beta blockers in MFS used the same out-
come of aortic dilatation as the primary outcome measure.
We also know that there is increasing use of ARBs among
patients with MFS even though there is no clear evidence
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there is an urgent need to complete studies of the efficacy
of ARBs in MFS.
Feasibility
MFS patients require lifelong monitoring and many need
major surgery. As a healthcare burden comparison there
are about 8,000 patients with Cystic Fibrosis in the UK
who generally require a greater level of ongoing health-
care support than MFS patients, but there are important
similarities in that both conditions are inherited, affect
young people, and reduce life expectancy.
MFS patients currently suffer great fear about their
long-term prognosis and if effective, irbesartan would
provide a lifesaving treatment option which could extend
life span into the normal range. There is tremendous
support from the medical community and lay MFS
population to perform this trial.
Aim of study
To investigate whether the angiotensin II receptor an-
tagonist irbesartan reduces the rate of aortic dilatation
in MFS compared to placebo.
Methods/Design
This trial is an investigator-led, prospective, randomized,
placebo-controlled, double-blind, phase III, multicenter





1. Clinically confirmed MFS using the revised Ghent
diagnostic criteria (2010)
2. Provision of informed consent
3. From ≥6 to ≤40 years of age inclusive.
Exclusion criteria
1. Previous cardiac or aortic surgery
2. Planned cardiac or aortic surgery at the time of
randomization
3. Aortic root Z-score ≤0
4. Aortic diameter ≥4.5 cm
5. Hemodynamically significant, severe valvular disease
(at the judgement of the treating clinician)
6. Heart failure, defined as left ventricular ejection
fraction <40%
7. Therapeutic use of angiotensin-converting-enzyme
(ACE) inhibitors/angiotensin II receptor antagonist
(patients on ACE inhibitors/angiotensin II receptorantagonists who discontinue this treatment are
required to have a 3-month wash-out period prior
to entry)
8. Previous recorded adverse reaction to the trial
medication (irbesartan) or any ACE inhibitor/
angiotensin II receptor antagonist
9. Female patients who are pregnant, planning
pregnancy, or not using reliable contraception
10. Known impaired renal function defined as
estimated creatinine clearance <60 mL/min, or
serum creatinine >150 μmol/L.
Concomitant treatments and procedures
Patients should generally continue all their concomitant
routinely indicated treatments including beta blockers.
Beta blocker use is not mandated by this protocol and
should be used at the judgement of the treating
physician.
Therapeutic use of ACE inhibitors or other angiotensin
II receptor antagonists during the trial is not permitted.
Patients are eligible for the trial if they have a 3-month
wash-out period (no ACE inhibitors/angiotensin II recep-
tor antagonists) prior to entry.
Screening, randomization, and unblinding
Screening
Potentially eligible patients will be screened at participat-
ing centers throughout the UK. All patients diagnosed
clinically as having MFS within the participating hospital
clinics will be screened for eligibility. Those who are
identified as potentially suitable will be approached to
see if they wish to participate. Written informed consent
will be requested before the patient is enrolled into the
study. Family members who are affected can also be
screened. Patients will be jointly supervised by the re-
sponsible cardiologist and geneticist at each site.
Randomization
Randomization will be carried out by an internet-based
randomization service. Investigators will be required to
confirm that the patient is eligible. Patients will be strati-
fied at randomization according to age (6 to 18 years
and >18 years of age), beta blocker use, and center.
Unblinding
Unblinding the allocation code can only be undertaken
in exceptional circumstances via the electronic case rec-
ord form (eCRF), when knowledge of the allocation is
essential for treating the patient, for example, suspected
unexpected serious adverse reaction (SUSAR) or other
serious adverse event (SAE). The Clinical Trials and
Evaluation Unit (CTEU) at the Royal Brompton and
Harefield NHS Foundation Trust, London, UK, will be
contacted before breaking the code. In all cases, the date
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Unblinding will occur at the individual patient-level
only.
Trial intervention
Study treatment will be in three phases:
1. Run-in phase: 75 mg once daily (OD) open-label
irbesartan for 4 weeks before randomization
2. Treatment phase: 150 mg (OD) active/placebo for
4 weeks before uptitration in appropriate patients
3. Treatment phase: 300 mg (OD) active/placebo
maximum tolerated dose for remaining treatment
period.
The proposed target doses are as follows: 300 mg OD
for patients >50 kg and 150 mg OD for patients ≤50 kg.
Patients will be monitored at regular intervals in the
baseline phase for tolerability to study medication in-
cluding general clinical examination, blood pressure,
electrolytes, and renal function. Compliance and toler-
ability will also be monitored by the study teams at 3-
month intervals by telephone, and should there be any
issues the patient will return to clinic for review. Indica-
tions for stopping the study drug would include any ap-
parent serious side effects, hypotension not amenable to
a reduction in study drug, pregnancy, or significant im-
pairment of renal function.
Study visits
Visit 0, run-in phase (month 1)
Eligible patients screened from outpatient clinics will be
invited to consent to the study. If the patient consents,
they will undergo a clinical examination including blood
pressure check and electrocardiography (ECG). Patients
will be dispensed with a 1-month supply of 75 mg open-
label irbesartan. This is to establish tolerance and compli-
ance to irbesartan prior to the baseline study visit. Patients
will also undergo the baseline echocardiogram and have
study-specific bloods taken for renal function, mutation
analysis (if not already taken as part of routine clinical
care), and TGF-β sub-study.
Visit 1, baseline (month 2)
Eligible patients who tolerate the open-label run-in
phase will have a clinical examination and baseline char-
acteristics recorded (height, weight, blood pressure,
heart rate). Patients will also undergo a compliance to
medication check, clinical evaluation including ECG,
medications review, liver function tests, full blood count,
urea and electrolytes, and renal function. Baseline medi-
cation will remain unchanged (beta blocker, other anti-
hypertensive, or nil).Patients will then be randomized into the trial using
the interactive voice recognition system (IVRS). A
unique identification number will be allocated to the pa-
tient, which will match the number on the study drug
held at the site pharmacy. Once allocated, the study drug
will be dispensed by the pharmacy. Patients will be pro-
vided with the 150 mg dose of irbesartan/placebo for
1 month. Children ≤50 kg will continue with the 150 mg
dose and will not be uptitrated.Visit 2, uptitration or maintenance visit (month 3)
Patients >50 kg will be uptitrated to the 300 mg dose of
irbesartan/placebo at month 3 if tolerated. Patients will
undergo a compliance to medications check, clinical
evaluation including blood pressure check, medications
review, liver function tests, full blood count, urea and
electrolytes, and renal function tests.
Patients who remain on the 150 mg dose will under-
take the visit procedures described above, although they
will not be dispensed the 300 mg dose.Visit *, titration visit (if necessary)
Patients who do not tolerate the maximum 300 mg dose
for whatever reason will be downtitrated to the 150 mg
dose and continue in the trial. At this visit, the patients
will have a clinical evaluation including blood pressure,
medications review, liver function tests, full blood count,
urea and electrolytes, and renal function tests, before the
150 mg dose is dispensed.Telephone checks (3-month intervals)
Subsequent to visit 2, there will be 3-month interval
telephone calls between the research team and patient to
check compliance to the medication and tolerability up
to month 60 (5 years). Should the patient have any prob-
lems they will return to the clinic for further review by
the research team.Annual visits (month 12, 24, 36, 48, and 60)
Patients will also have an annual follow-up at month 12,
24, 36, 48, and 60 (depending on entry to the trial) as
per routine clinical care to undergo a compliance to
medication check, clinical evaluation including blood
pressure, ECG, medications review, liver function tests,
full blood count, urea and electrolytes, renal function,
and drug dispensing. Patients will also undergo an an-
nual echocardiogram for analysis. At year 1, an annual
study-specific blood sample will be taken for analysis for
the TGF-β sub-study.
Study procedures and follow-up are described in
Table 1.
Table 1 Study-related investigations and follow-up
























































√ √ √ √ √ √ √ √ √ √ √
Clinical
evaluation





Blood pressure √ √ √ √ √ √ √ √ √
Echocardiogram √ √ √ √ √ √
ECG √ √ √ √ √ √ √
Medications √ √ √ √ √ √ √ √ √
Liver function √ √ √ √ √ √ √ √
Full blood count √ √ √ √ √ √ √ √
Urea and
electrolytes
√ √ √ √ √ √ √ √
Renal function √ √ √ √ √ √ √ √ √
Study drug
given
























Mullen et al. Trials 2013, 14:408 Page 7 of 14
http://www.trialsjournal.com/content/14/1/408Participant follow-up
Patients will also be followed up via the NHS Informa-
tion Centre Medical Research Information Service for a
minimum of 20 years after the end of study follow-up.
Pregnancy
Women of childbearing potential (able to have children)
are required to use reliable forms of contraception if taking
part in the study (including barrier and/or oral methods).
Women of childbearing potential will be excluded if plan-
ning pregnancy during the trial period or sexually active
and not using a reliable form of contraception.
Patient withdrawal
Temporary discontinuation of investigational medicinal
product (IMP)
There should be no reason to discontinue the study drug
unless in exceptional circumstances such as side effects,
for example renal impairment or significant hypotension.
In such cases, the investigator should downtitrate or dis-
continue the study medication as required. Reintroduc-
tion of the study medication should be monitored and
uptitration undertaken as required.
Permanent discontinuation of IMP
Patients may permanently withdraw from treatment with
the investigational medicinal product (IMP) if they de-
cide to do so, at any time and for any reason, or this
may be the investigator’s decision. If there is considered
to be a concern about the batch of IMP, recall proce-
dures will be in place and measures will be taken to en-
sure the safety of all trial participants.
Withdrawal from trial procedures and incomplete follow-up
Patients are free to withdraw consent from trial proce-
dures at any time. Investigators must ascertain the rea-
sons for the withdrawal including discontinuation of
study drug, withdrawal from study investigations and/or
follow-up, withdrawal due to adverse events, failure to
attend, non-compliance, withdrawal of consent, or other
reasons. The withdrawal form must be faxed to the
CTEU within 5 working days, unless withdrawal is due
to a SAE, in which case the investigator will follow SAE
reporting procedures.
Withdrawal from trial procedures may result in in-
complete patient follow-up and failure to capture out-
come data. In these cases as much data as possible will
be collected, up until the point of withdrawal. Patients
may choose to withdraw from trial procedures and re-
quest that further data are not collected.
Enrolment and participating centers
Based on 26 centers recruiting, we expect an approximate
recruitment rate of one patient/month/center, which willenable 490 patients to be recruited over a 2-year enrol-
ment window. The study will run for 66 months (5.5 years)
split into four periods as follows:
1. Start-up: 6 months
2. Enrolment: 24 months (with potential to extend into
the third year if necessary)
3. Follow-up: 36 months minimum (patients enrolled
at the start of the study will be followed up for a
maximum of 60 months, thus the mean follow-up
period is 48 months)
4. Closeout: 6 months.
Outcome measures
Primary outcome measure
The primary outcome measure will be the absolute
change in aortic root diameter per year measured by echo-
cardiography. Echo measurements will be taken by trans-
thoracic echocardiograms (TTEs) performed at baseline
and annually thereafter in order to assess the annual
change of aortic dilatation.
Secondary outcome measures
The secondary outcome measures are as follows:
1. Change in Z-score per year, where the Z-score is
calculated on aortic root and body surface area (BSA)
2. Clinical events and requirement for surgery
including aortic dissection confirmed by
transesophageal echocardiography (TEE), MRI, or
CT, aortic dissection requiring emergency surgery,
aortic dissection requiring elective surgery, aortic
dilatation requiring elective or emergency surgery,
death (all causes and classified by suspected cause),
cerebrovascular accident, cardiovascular death,
aortic regurgitation requiring surgery, or death
during surgery for any of the above
3. Left ventricular function determined by volumes and
ejection fraction
4. Left ventricular mass measurements
5. Assessment of valvular function
6. Cardiac rhythm and voltage
7. Height, weight, arm span, and lower segment
measurements
8. Fibrillin-1 mutation analysis will be performed for
those patients whose mutation status is unknown.
Echocardiography
Aortic dilatation will be measured by echocardiography.
All annual echocardiograms will be analyzed by an
established echo core laboratory. Patients will be seen in
centers that have routine access to standard M-mode,
two-dimensional (2-D) echocardiography. Transthoracic
M-mode, 2-D, and Doppler echocardiograms will be
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standardized protocol. Each center will be trained on the
standardized protocol prior to commencing the trial.
Aortic root diameter will be measured at the annulus, in
the sinuses of Valsalva at the tip of the open cusps at 90°
to the direction of flow, the sinotubular junction, as-
cending aorta, aortic arch, and descending aorta.
Each echocardiogram will be sent electronically to the
echocardiographic core laboratory at the John Radcliffe
Hospital, Oxford, UK, where a single experienced inves-
tigator will supervise the reading and interpretation of
all echocardiograms according to a standardized proto-
col to reduce variability due to observer variation. The
echo core laboratory will be blinded to the study drug
allocation to eliminate any bias in echo measurement.
Quality control processes will be developed as part of
the echo protocol. The echocardiographic protocol is in-
cluded in Additional file 1.Fibrillin-1 mutation analysis at baseline
There is a 92% chance of finding a mutation in classical
MFS. For patients who have not already had fibrillin-1
mutation screening, but who are considered clinically af-
fected with MFS, a 5 mL EDTA blood sample will be
collected and stored for assay. Samples will be analyzed
and funded as per usual local arrangements.
Samples from units which do not have funding for
these tests should be sent directly to the Sonalee Labora-
tory, St. George’s, University of London, London, UK
[3]. Samples will be entered in the research program
assay, and research laboratory reports will be issued.
A separate genetic sub-study will be undertaken to in-
vestigate the correlation between the response to medi-
cation and the site and type of mutation which
determine the phenotype [4,39,40]. Patients will consent
to this sub-study separately from the main trial.Additional investigations and sub-studies
To increase knowledge about the underlying disease and
the potential mechanism of action of ARBs, several sub-
studies are proposed. The main proposed sub-studies are:
1. Genetic sub-studies: a) fibrillin-1 mutation analysis;
and b) pharmacogenetics sub-study
2. Total circulating TGF-β1.Data collection
Electronic case record form (eCRF)
Trial data will be captured on a web-based eCRF. The eCRF
will be designed in accordance with the requirements of the
trial protocol and will comply with regulatory requirements.
Access to the eCRF will be password-protected.Pharmacovigilance
The Royal Brompton and Harefield NHS Foundation
Trust (Sponsor) has delegated responsibility for pharma-
covigilance to the trial coordinating center, the CTEU of
the Royal Brompton and Harefield NHS Foundation
Trust. The CTEU will be responsible for recording all
reported SAEs from investigational trial sites, and expe-
dited reporting of SUSARs in accordance with statutory
regulations.
Adverse event (AE)
An adverse event (AE) is defined as any untoward med-
ical occurrence in a patient or clinical trial subject ad-
ministered a medicinal product and which does not
necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended
sign (including an abnormal laboratory finding), symptom,
or disease temporally associated with the use of an IMP,
whether or not considered related to the IMP.
Adverse reaction (AR)
Adverse reactions (ARs) are all untoward and unin-
tended responses to an IMP related to any dose adminis-
tered. All AEs judged by either the reporting investigator
or the sponsor as having reasonable causal relationship
to a medicinal product qualify as ARs.
In the event an AR is reported during the trial, investi-
gators will assess the severity of the AE using the follow-
ing criteria, detailed on the AE report form in the eCRF:
1. Mild: awareness of signs or symptoms, but easily
tolerated; are of minor irritant type; causing no loss
of time from normal activities; symptoms would not
require medication
2. Moderate: discomfort severe enough to cause
interference with usual activities
3. Severe: inability to do work or usual activities; signs
and symptoms may be of systemic nature or require
medical evaluation and/or treatment.
Unexpected adverse reaction (UAR)
An unexpected adverse reaction (UAR) is an AR, the
nature or severity of which is not consistent with the ap-
plicable product information (summary of product charac-
teristics, SmPC). When the outcome of the AR is not
consistent with the applicable product information this AR
should be considered as unexpected. Side effects docu-
mented in the SmPC which occur in a more severe form
than anticipated are also considered to be unexpected.
Expected drug-related AR
Expected drug-related ARs will be referred to the SmPC
as provided and the summary in Additional file. Symp-
tomatic hypotension defined as systolic blood pressure
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cope on standing is considered an expected AR and will
be reported on a specific AE form. Any other AR will be
reported on a generic AE form on the eCRF.
Reporting ARs
Investigators will report all ARs on the AE report form
in the eCRF including information of the event, details
of date of onset, frequency, severity, and potential rela-
tionship to treatment, outcomes, and action taken. In-
vestigators will make a clinical judgement as to the
appropriate action required depending on the severity of
the reaction. This could include monitoring the patient
over a period of time, interrupting the drug regime, dis-
continuing the patient from the trial, or continuing with
the trial as specified. Investigators will submit AE re-
ports to the CTEU after each patient visit. The CTEU
will maintain a database of all ARs. AEs will be reviewed
at regular intervals by the Data Monitoring Committee
(DMC) for signal and trend analysis.
Serious adverse events (SAEs)/reactions
SAEs or reactions are defined as any untoward medical
occurrence or effect that at any dose results in death, is
life threatening, requires hospitalization or prolongation
of existing inpatient hospitalization, results in persistent
or significant disability or incapacity, or is a congenital
anomaly or birth defect.
Should a study participant become pregnant while
undertaking the trial, or aid in the conception of a child
while they are participating in the trial, the pregnancy and
resulting child should be followed up for a period of no
less than 18 months. In this trial should a child be
followed up and diagnosed with MFS, this would not be
considered unexpected due to the nature of the syndrome.
Expected SAEs (as a result of the underlying disease)
Expected SAEs as a result of the underlying disease in-
clude: admission or procedure for MFS including treat-
ment for cardiovascular, musculoskeletal, ocular, and
thoracic complications; aortic dissection; aortic regurgi-
tation requiring surgery; emergency or elective aortic
root and/or valve replacement surgery; cerebrovascular
accident; and cardiovascular death, sudden death, or
death during surgery.
Expected SAEs will be reported as per the usual data
capture requirements for the study and are not subject
to expedited reporting.
Other SAEs which are not expected irrespective of
causality will be subject to SAE reporting requirements.
In the event of an SAE, investigators will report details
on the SAE form on the eCRF including date of event,
admissions, diagnosis details, date of discharge, or death.
SAE reports must be completed within 24 hours of theinvestigator’s knowledge of the SAE. Investigators will be
able to submit follow-up SAE reports should further in-
formation become available. Investigators will be ex-
pected to assess and assign causality and expectedness
of each event on the form using the definitions described
below. The CTEU will review all SAE reports. The Chief
Investigator/deputy will review the SAE reports and in-
form the CTEU of the assessment.
Definitions for assessment of causality
The definitions for assessment of causality include:
1. Unrelated: there is no evidence of any causal
relationship
2. Unlikely: there is little evidence to suggest there is a
causal relationship (for example the event did not
occur within a reasonable time after administration
of the trial medication). There is another reasonable
explanation for the event (for example the patient’s
clinical condition, other concomitant treatment)
3. Possible: there is some evidence to suggest a causal
relationship (for example because the event occurs
within a reasonable time after administration of the
trial medication). However, the influence of other
factors may have contributed to the event (for
example the patient’s clinical condition, other
concomitant treatments)
4. Probable: there is evidence to suggest a causal
relationship and the influence of other factors is
unlikely
5. Definitely: there is clear evidence to suggest a causal
relationship and other possible contributing factors
can be ruled out
6. Not assessable: there is insufficient or incomplete
evidence to make a clinical judgement of the causal
relationship.
Suspected unexpected serious adverse reactions (SUSARs)
A serious adverse reaction (SAR) can be considered un-
expected when the AR is not consistent with the applic-
able product information or expected SAEs listed above.
All SUSARs related to an IMP, which occur during the
trial, are subject to expedited reporting. Where applic-
able, if an event is considered a SUSAR, the patient
should be unblinded from the study allocation.
Reporting of SUSARs
A full and detailed account of the SAE must be recorded
on the SAE report. The SAE report must be completed
within 24 hours. A medical summary should also be faxed
to the CTEU within 24 hours. The Chief Investigator/
deputy will review the report and summary and inform
the CTEU of the assessment.
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All SUSARs will be reported to the Medicines and
Healthcare Products Regulatory Agency (MHRA) and
NHS Research Ethics Committee (REC) by the CTEU.
All SUSAR reports will be unblinded prior to submis-
sion. A SUSAR which is fatal or life threatening will be
reported to the MHRA and the main REC by the CTEU
as soon as possible and within 7 days of knowledge of
the event. A SUSAR which is not fatal or life threatening
must be reported to the MHRA and the main REC as
soon as possible and within 15 days of knowledge of the
event. The CTEU will inform all relevant parties of any
reported SUSARs within 15 working days.Annual reporting
The CTEU will submit annual safety reports of all sus-
pected SARs in accordance with regulatory requirements
to the MHRA and the main REC. Annual safety reports
will be submitted to the MHRA on the date of the ori-
ginal clinical trials authorization. Annual progress re-
ports will also be submitted to the main REC. There is
no requirement for local trial sites to submit progress re-
ports to local RECs.Statistical considerations
Sample size calculation
The primary outcome is absolute change in aortic root
diameter per year. The sample size calculation was based
on estimates obtained from a database of MFS patients
maintained by AC, co-investigator and lead Geneticist.
Information was extracted from this database for all pa-
tients who met the following criteria: age at first echo
between 6 and 40 years; at least two serial echo mea-
surements; and time between the first and last valid
measurement between 0.9 and 5.1 years.
This provided a database of 254 patients who had a
median (interquartile range) follow-up time of 3.4 (2.4,
4.5) years. The data were cleaned and reviewed and dur-
ing this time the average rate of aortic dilatation was ap-
proximately 1 mm per year, with a standard deviation of
1.8 mm. Table 2 shows the number of patients required
to test for a difference between an annual dilatation rate











318 318irbesartan. This is based on achieving 80% power and
testing at the 5% significance level.
By inspection of this table, to detect a 0.5 mm change
in dilatation rate would require 204 patients in each
group. Allowing for a 20% drop-out (including missing
data and non-compliance) we aim to recruit 245 patients
in each group, making a total of 490 patients. Expansion
rates according to treatment group would be regularly
reviewed by the independent Data and Safety Monitor-
ing Committee (DSMC) who would advise the Steering
Committee if there was clear evidence of benefit before
the scheduled end of the study, or alternatively may ad-
vise if there is no real possibility of finding a difference
(performing a ‘futility’ analysis) either because irbesartan
does not have the expected effects, or if aortic expansion
rates are slower than expected in the control group. We
have selected a proportional reduction of 50% of dilatation
rate per annum (0.5 mm) largely on pragmatic grounds. If
irbesartan only offered a very modest reduction in rate we
are much less certain that this could be translated into a
clinical benefit. We are also measuring a surrogate out-
come (aortic dilatation) but one which is closely related to
adverse clinical events in this population.
Statistical analysis
The primary analysis in this study is the comparison of
the rate of annual aortic dilatation in those patients
treated with irbesartan compared to placebo. The annual
rate of dilatation will be calculated by estimates of mean
values of the annual echocardiograms adjusting the time
of follow-up to a ‘common’ start point, that is, the base-
line measurement. An independent samples t-test will be
used to test for a difference in the rate between the irbe-
sartan and placebo groups, assuming that the measure-
ment of annual dilation follows a normal distribution.
Analysis of covariance (ANCOVA) will be used if the
analysis of the primary outcome is adjusted for any other
variables. The primary analysis will be carried out ac-
cording to the intention-to-treat principle in which all
randomized patients will be included according to their
initial randomized allocation irrespective of whether they
continue to take the assigned treatment or not. Patients
who are not followed up to the end of the study for












Mullen et al. Trials 2013, 14:408 Page 11 of 14
http://www.trialsjournal.com/content/14/1/408included in the analysis. Patients will be followed from
the time of randomization to the end of the study
period. Thus individual patients will have a variable
follow-up period. No formal method for imputing miss-
ing aortic diameter values is proposed as the comparison
will be performed on the mean of group data. Secondary
analyses include comparison of other measurements
using appropriate comparative and descriptive statistics.
Regulatory and ethical considerations
Regulatory framework and approval
This study is a randomized trial of an IMP (licensed
product in new conditions of use; new dosing schemes/
new target population), and as such will comply with the
European Clinical Trials Directive and the Medicines for
Human Use (Clinical Trials) Regulations 2004. A clinical
trial authorisation (CTA) has been granted from the
MHRA. The study is registered in the European Clinical
Trials Database with a European Union Drug Regulating
Authorities Clinical Trials (EudraCT) number.
Ethical approval
The trial will comply with the Declaration of Helsinki
(http://www.wma.net/) on research involving human
subjects. The study protocol, patient information sheet,
and consent form have been approved by the NHS
National Research Ethics Service (NRES) and subse-
quently the research and development departments of
each participating center for site-specific approval. The
AIMS trial is also approved on the National Institute for
Health Research (NIHR) portfolio.
Monitoring
Initiation visit
Before the study commences, each trial site will receive
a training visit from the CTEU where required. The pur-
pose of these visits will be to ensure that the local research
team (local principal investigator, co-investigators, study
coordinator, and pharmacists) fully understand the proto-
col, eCRF, and the practical procedures for the study.
Interim monitoring visits
At regular intervals during the study, the CTEU will per-
form monitoring visits to each trial site. The purpose of
these visits is to ensure compliance with the protocol
and that ethical and regulatory requirements are met.
Source data verification (SDV) and checking of essential
documents will be performed. Monitors will also visit
the pharmacy departments to review study procedures,
storage, and accountability of the IMP.
Monitoring visits also provide an opportunity for fur-
ther training if required (for example new staff ). Central
review of study data will also be performed throughout
the study by the data management team at the CTEU.Closeout visit
At the end of the study, each trial site will receive a
closeout visit from the CTEU to resolve any outstanding
edit queries or AEs and to verify the archiving proce-
dures for study documentation.
Trial organization and committees
Study management
The study will be sponsored by the Royal Brompton and
Harefield NHS Foundation Trust. The Chief Investigator
will be MM at the Royal Brompton Hospital, London,
UK. AC at St George’s Hospital will be the lead Geneti-
cist and XYJ at the John Radcliffe Hospital will be the
lead Echocardiologist for the study. All participating cli-
nicians have extensive experience of running MFS diag-
nostic clinics. A Trial Steering Committee (TSC), DMC,
and Trial Management Group will be convened to over-
see the trial. Central coordination of this clinical trial
will be provided by the CTEU.
Trial Steering Committee (TSC)
The main role of the TSC is to monitor and supervise
the progress of the trial. The composition of the TSC
will comply with Medical Research Council (MRC)
guidelines with an independent Chair and lay represen-
tation as well as the Chief Investigator and main co-
investigators. The TSC will meet regularly throughout
the study.
Data Monitoring Committee (DMC)
All members of the DMC are independent of the trial.
The DMC will meet prior to the start of the trial and
then one and two thirds of the way through the trial, or
as required thereafter. The DMC will be expected to de-
velop, in agreement with the investigators, a charter out-
lining their responsibilities and operational details.
Study coordination
The study will be coordinated and managed by the
CTEU, a dedicated clinical trials department within the
Royal Brompton Hospital. In addition to providing over-
all project coordination, the CTEU will assist in prepar-
ing the final protocol, the investigators’ manuals, design
the eCRF, provide the randomization service and design,
and instigate the data management system. The CTEU
will ensure that the trial runs according to the pre-agreed
timetable, recruitment targets are met, eCRFs are com-
pleted accurately, compliance with relevant ethical and
regulatory standards, and that all aspects of the study are
performed to the highest quality. The CTEU will also as-
sist in the training of investigators and coordinators at the
start-up of the study and for performing monitoring and
pharmacovigilance procedures throughout.
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Investigators are required to ensure compliance to the
protocol and all statutory regulations and guidelines,
eCRFs, and manual of operations. Investigators are re-
quired to allow access to study documentation or source
data on request for monitoring visits and audits per-
formed by the CTEU, sponsor, or any regulatory
authorities.
End of trial
The end of trial will be declared when the last patient
recruited completes the last follow-up visit, that is, echo-
cardiogram at 36 months follow-up visit.
Investigational medicinal products
Manufacture
The study drug (irbesartan and placebo) will be pur-
chased from the commercial supplier, Sanofi-Aventis,
Guildford, Surrey, UK, which holds the manufacturing
license to produce the IMP.
Brecon Pharmaceuticals Ltd, Hay-on-Wye, UK, will
undertake to prepare, pack, and label the IMPs and dis-
tribute as required throughout the trial. The IMP supply
will be labeled in accordance with regulatory require-
ments and specifications and will be approved by the
MHRA as part of the application for CTA.
Storage and dispensing
The study drug patient kit for the 1-month run-in phase,
baseline phase, and uptitration phase (month 1 to 3) will
be stored in a secure area of the pharmacy, under the
conditions described in the respective SmPC.
The IMP supply will be dispensed by the local phar-
macy which will be responsible for maintaining a record
of accountability.
Continuation packs of the study drug will be dispensed
direct to patient homes on a 3-month supply basis by
Brecon Pharmaceuticals Ltd. Drug accountability re-
cords will be supplied as required.
Publication policy and dissemination of results
The results from the trial will be submitted for publica-
tion in a major journal irrespective of the outcome. The
TSC will be responsible for approval of all manuscripts
arising from the study prior to submission for publica-
tion. Sub-studies of center-specific data may only be car-
ried out with the knowledge and approval of the TSC.
Sub-study publications must not be published prior to
the publication of the main study.
All publications and presentations will make appropri-
ate acknowledgement of the contribution of the collab-
orative group. At the end of the study, patients will be
able to request a copy of the results of the study from
the investigator at that site.Trial status
The first patient was enrolled in March 2012, and re-
cruitment is ongoing.
Additional file
Additional file 1: Appendices.
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